Monoclonal antibody therapies in the management of SARS-CoV-2 infection.

ABSTRACT:

Introduction

Neutralizing antibodies (NAbs) that target key domains of the spike protein in severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) may have therapeutic value because of their specificity. Depending on the targeted epitope, single agents may be effective, but combined treatment involving multiple NAbs may be necessary to prevent the emergence of resistant variants.

Areas covered

This article highlights the accelerated regulatory processes established to facilitate the review and approval of potential therapies. An overview of treatment approaches for SARS-CoV-2 infection, with detailed examination of the preclinical and clinical evidence supporting the use of NAbs, is provided. Finally, insights are offered into the potential benefits and challenges asso

SUBMITTER: Miguez-Rey E 

PROVIDER: S-EPMC8862171 | biostudies-literature | 2022 Jan

REPOSITORIES: biostudies-literature